Breaking News Instant updates and real-time market news.

PG

Procter & Gamble

$92.64

-1.76 (-1.86%)

06:04
09/22/17
09/22
06:04
09/22/17
06:04

Trian identifies numerous errors in recent Procter & Gamble presentation

Trian Fund, whose investment funds beneficially own approximately $3.5B of shares of The Procter & Gamble Company, released a response to P&G's September 19th investor presentation, highlighting a significant number of material data errors, calculation errors and misrepresentations about Nelson Peltz's track record contained in the presentation. Trian has identified more than 50 errors and misrepresentations to date. "We are disappointed in the quality of the presentation that the Board and Management of Procter & Gamble released on September 19, 2017 which is filled with a significant number of material data errors, calculation errors and misrepresentations of Trian's and Nelson Peltz's track records (we have identified more than 50 errors and misrepresentations to date). P&G has apparently tasked its army of advisors with discrediting Nelson Peltz and Trian in order to redirect the conversation away from the real issues at hand - in particular P&G's ongoing market share losses and bottom quartile shareholder returns. We feel it is necessary to "set the record straight" as shareholders and other constituencies deserve to understand the level of P&G's intellectual dishonesty we believe underlies this presentation. We would like P&G to correct these errors, but ultimately it is shareholders who must hold the Company accountable. Our goal from now until the shareholder vote on October 10 is to focus on the critical issues facing P&G and the eight strategic initiatives detailed in our White Paper that we believe can help P&G regain lost market share and once again achieve best-in-class performance. We respect the Company's right to debate our points of view on these critical issues, but find these misrepresentations of Nelson Peltz unacceptable. The reality is, Nelson Peltz's track record speaks for itself - every Trian investment on whose board Nelson Peltz has served has outperformed P&G during Trian's involvement. Management would like shareholders to believe that P&G has a "strategy that is working" and that performance has improved meaningfully under David Taylor. This is not true. The facts are that since David Taylor took over as CEO, the Company has continued to lose market share in every reportable segment, in both FY 2016 and FY 2017, as reported in P&G's Annual Reports filed with the SEC. In addition, since David Taylor took over as CEO, P&G has seen core earnings per share decline from $4.02 to $3.92 (as reported each fiscal year). While P&G would like you to believe that its strategy drove 7% earnings per share growth last year, the reality is that 5 percentage points of the 7% came from share buybacks using proceeds from divestitures, and from cutting advertising spend by $125M."

PG Procter & Gamble
$92.64

-1.76 (-1.86%)

09/19/17
JEFF
09/19/17
NO CHANGE
Target $104
JEFF
Buy
Jefferies sees Trian as 'win-win' for P&G shareholders
After meeting with Nelson Peltz and the Trian team, Jefferies analyst Kevin Grundy continues to recommend shares of Procter & Gamble. Trian's involvement raises the execution bar, setting up a "win-win" for shareholders, Grundy tells investors in a research note. He raised his price target for P&G shares to $104 from $103 and keeps a Buy rating on the name.
09/14/17
MACQ
09/14/17
INITIATION
Target $102
MACQ
Outperform
Procter & Gamble initiated with an Outperform at Macquarie
Macquarie analyst Caroline Levy initiated Procter & Gamble with an Outperform and a $102 price target. Levy said there are early signs of improvements and expects activist Nelson Peltz to "prod" the company to move faster in shifting management control and responsibility to local markets and pay for performance.
08/17/17
JEFF
08/17/17
NO CHANGE
Target $103
JEFF
Buy
Procter & Gamble remains a core Staples holding, says Jefferies
Jefferies analyst Kevin Grundy continues to recommend shares of Procter & Gamble as core Staples holding following "upbeat" meetings with management. Trian's involvement, while a distraction, has raised the execution bar, Grundy tells investors in a research note. The analyst notes that the company sees little merit in adding Trian to the board. Grundy believes P&G's structural and portfolio changes are "bearing fruit" and that shares offer multiple expansion potential from current levels. He keeps a Buy rating on the shares with a $103 price target.
07/17/17
DBAB
07/17/17
NO CHANGE
Target $90
DBAB
Hold
Procter & Gamble unlikely to miss near-term expectations, says Deutsche Bank
Deutsche Bank analyst Faiza Alwy believes Procter & Gamble's decision to not give Trian's Nelson Peltz a board seat as a sign that management is confident in its strategy and is unlikely to miss expectations over at least the next few months. The analyst notes the Wall Street Journal's reporting indicates that contrary to speculation from analysts, Trian is not seeking a breakup of the company. This idea was a non-starter given substantial dis-synergies and tax leakage, Alwy tells investors in a research note. The analyst keeps a Hold rating on the shares with a $90 price target.

TODAY'S FREE FLY STORIES

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

, SNY

Sanofi

$39.91

0.19 (0.48%)

08:32
02/19/18
02/19
08:32
02/19/18
08:32
Recommendations
AnaptysBio, Sanofi, Regeneron analyst commentary  »

AnaptysBio price target…

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

SNY

Sanofi

$39.91

0.19 (0.48%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 25

    Mar

  • 02

    May

  • 03

    May

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

08:26
02/19/18
02/19
08:26
02/19/18
08:26
Hot Stocks
AnaptysBio presents updated Phase 2 data for ANB020 in atopic dermatitis »

AnaptysBio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

NWL

Newell Brands

$28.23

0.59 (2.13%)

08:20
02/19/18
02/19
08:20
02/19/18
08:20
Recommendations
Newell Brands analyst commentary  »

Newell Brands price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

AZN

AstraZeneca

$33.93

-0.09 (-0.26%)

08:17
02/19/18
02/19
08:17
02/19/18
08:17
Recommendations
AstraZeneca analyst commentary  »

AstraZeneca approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 23

    Apr

ABGLF

Acacia Mining

08:13
02/19/18
02/19
08:13
02/19/18
08:13
Upgrade
Acacia Mining rating change  »

Acacia Mining upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPAM

Epam Systems

$114.95

2.72 (2.42%)

08:08
02/19/18
02/19
08:08
02/19/18
08:08
Recommendations
Epam Systems analyst commentary  »

Epam Systems price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:05
02/19/18
02/19
08:05
02/19/18
08:05
General news
FX Update: The dollar has been trading on a firmer footing »

FX Update: The dollar…

GTES

Gates Industrial

$18.29

-0.09 (-0.49%)

08:05
02/19/18
02/19
08:05
02/19/18
08:05
Initiation
Gates Industrial initiated  »

Gates Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.36

1.28 (4.40%)

08:03
02/19/18
02/19
08:03
02/19/18
08:03
Initiation
PagSeguro Digital initiated  »

PagSeguro Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.36

1.28 (4.40%)

08:02
02/19/18
02/19
08:02
02/19/18
08:02
Initiation
PagSeguro Digital initiated  »

PagSeguro Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTP

Midatech Pharma

$0.98

-0.0099 (-1.00%)

04:55
02/19/18
02/19
04:55
02/19/18
04:55
Conference/Events
Midatech Pharma management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 27

    Feb

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/19/18
02/19
04:55
02/19/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 07

    Jun

  • 13

    Nov

03:05
02/19/18
02/19
03:05
02/19/18
03:05
General news
FX Update: The dollar traded generally firmer »

FX Update: The dollar…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/18/18
02/18
04:55
02/18/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 13

    Nov

MRVL

Marvell

$22.68

-0.06 (-0.26%)

, CAVM

Cavium

$87.16

-0.09 (-0.10%)

14:55
02/17/18
02/17
14:55
02/17/18
14:55
Conference/Events
Cavium to host special shareholder meeting »

Special Shareholder…

MRVL

Marvell

$22.68

-0.06 (-0.26%)

CAVM

Cavium

$87.16

-0.09 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 08

    Mar

CAVM

Cavium

$87.16

-0.09 (-0.10%)

, MRVL

Marvell

$22.68

-0.06 (-0.26%)

14:51
02/17/18
02/17
14:51
02/17/18
14:51
Conference/Events
Marvell to host special shareholder meeting »

Special Shareholder…

CAVM

Cavium

$87.16

-0.09 (-0.10%)

MRVL

Marvell

$22.68

-0.06 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

DEL

Deltic Timber

$98.45

1.77 (1.83%)

, PCH

Potlatch

$54.75

0.75 (1.39%)

14:45
02/17/18
02/17
14:45
02/17/18
14:45
Conference/Events
Potlatch to host special shareholder meeting »

Special Shareholder…

DEL

Deltic Timber

$98.45

1.77 (1.83%)

PCH

Potlatch

$54.75

0.75 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

PCH

Potlatch

$54.75

0.75 (1.39%)

, DEL

Deltic Timber

$98.45

1.77 (1.83%)

14:42
02/17/18
02/17
14:42
02/17/18
14:42
Conference/Events
Deltic Timber to host special shareholder meeting »

Special shareholder…

PCH

Potlatch

$54.75

0.75 (1.39%)

DEL

Deltic Timber

$98.45

1.77 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$20.42

0.67 (3.39%)

09:31
02/17/18
02/17
09:31
02/17/18
09:31
Periodicals
Snap CEO sold $50M in stock this week, Recode reports »

Snap CEO Evan Spiegel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

, MPSYY

MorphoSys

$46.29

1.29 (2.87%)

09:27
02/17/18
02/17
09:27
02/17/18
09:27
Hot Stocks
Galapagos NV, MorphoSys present results from Phase 1 study with MOR106 in AD »

Galapagos NV (GLPG) and…

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

MPSYY

MorphoSys

$46.29

1.29 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$360.53

-0.47 (-0.13%)

09:22
02/17/18
02/17
09:22
02/17/18
09:22
Hot Stocks
Lockheed Martin receives Freedom-variant FFG conceptual design contract »

The U.S. Navy awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

  • 30

    May

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

, UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

09:11
02/17/18
02/17
09:11
02/17/18
09:11
Periodicals
Bears, bulls battle over Under Armour, Barron's says »

In a follow-up story,…

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOV

Hovnanian

$2.24

0.12 (5.66%)

09:04
02/17/18
02/17
09:04
02/17/18
09:04
Periodicals
Hovnanian stock too cheap to ignore, Barron's says »

Hovnanian Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

, JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

09:00
02/17/18
02/17
09:00
02/17/18
09:00
Periodicals
JPMorgan, Walmart cash flow yields exceed dividend yields, Barron's says »

The cash flow yields of…

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 30

    May

  • 14

    Jul

  • 12

    Oct

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

, GOOG

Alphabet

$1,094.80

5.28 (0.48%)

08:56
02/17/18
02/17
08:56
02/17/18
08:56
Periodicals
Alphabet, Citi well positioned for later stages of market rally, Barron's says »

It is time for investors…

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 18

    Mar

  • 28

    Mar

  • 29

    Mar

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.